Patent · US Active

Immunogenic composition

US12076352B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Christiane Feron · Rixensart, BE
Sandra Giannini · Rixensart, BE

Key dates

Filing date	Jun 18, 2019
Grant date	Sep 3, 2024
Priority date	—
Expiry date	Sep 15, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention discloses an engineered bacteriophage capable of binding to a commensal bacterium and inserting its genome polynucleotide into the commensal bacterium, but incapable of producing progeny, incapable of carrying out a lysogenic cycle and incapable of carrying out a lytic cycle within the commensal bacterium, wherein the engineered bacteriophage comprises a genome polynucleotide including at least one gene encoding at least one heterologous antigen(s) under the control of a promoter.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.